Evaluating sleep and cognition in HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 609-616

  Gamaldo, Charlene E ^a   Gamaldo, Alyssa ^b   Creighton, Jason ^a   Salas, Rachel E ^a   Selnes, Ola A ^a   David, Paula M ^a   Mbeo, Gilbert ^a   Parker, Benjamin S ^a   Brown, Amanda ^a   McArthur, Justin C ^a   Smith, Michael T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cognition; HIV; Quality of life; Sleep; Sleep disorders

Indexed keywords

ANTIRETROVIRUS AGENT;

ACTIMETRY; ADULT; ANTIVIRAL THERAPY; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; EXECUTIVE FUNCTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA SEVERITY INDEX; MALE; NEUROPSYCHOLOGICAL TEST; PITTSBURGH SLEEP QUALITY INDEX; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUESTIONNAIRE; SELF REPORT; SLEEP DEPRIVATION; SLEEP PATTERN; SLEEP QUALITY; SLEEP TIME;

ADULT; ANTI-RETROVIRAL AGENTS; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYSOMNOGRAPHY; PREVALENCE; SLEEP DISORDERS;

EID: 84883461624     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829d63ab     Document Type: Article

References (60)

1. McArthur JC, Steiner J, Sacktor N, et al. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699-714. doi:10.1002/ana.22053.
2. Wright EJ, Nunn M, Joseph J, et al. NeuroAIDS in the Asia Pacific Region. J Neurovirol. 2008;14:465-473. doi:10.1080/13550280802235932.
3. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75:2087-2096. doi: 10.1212/WNL.0b013e318200d727.
4. Reid S, Dwyer J. Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med. 2005;67: 260-269. doi:10.1097/01.psy.0000151771.46127.df.
5. Ram S, Seirawan H, Kumar SK, et al. Prevalence and impact of sleep disorders and sleep habits in the United States. Sleep Breath. 2010;14: 63-70. doi:10.1007/s11325-009-0281-3.
6. Norman SE, Chediak AD, Freeman C, et al. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep. 1992;15:150-155.
7. Norman SE, Chediak AD, Kiel M, Cohn MA. Sleep disturbances in HIVinfected homosexual men. AIDS. 1990;4:775-781.
8. Cruess DG, Antoni MH, Gonzalez J, et al. Sleep disturbance mediates the association between psychological distress and immune status among HIV-positive men and women on combination antiretroviral therapy. J Psychosom Res. 2003;54:185-189.
9. Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med. 2007;3:519-528.
10. Jones K, Harrison Y. Frontal lobe function, sleep loss and fragmented sleep. Sleep Med Rev. 2001;5:463-475.
11. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. 2005;25:117-129.
12. Killgore WD, Balkin TJ, Wesensten NJ. Impaired decision making following 49 h of sleep deprivation. J Sleep Res. 2006;15:7-13.
13. Drummond SP, Paulus MP, Tapert SF. Effects of two nights sleep deprivation and two nights recovery sleep on response inhibition. J Sleep Res. 2006;15:261-265.
14. Harrison Y, Jones K, Waterhouse J. The influence of time awake and circadian rhythm upon performance on a frontal lobe task. Neuropsychologia. 2007;45:1966-1972.
15. Bolla KI, Lesage SR, Gamaldo CE, et al. Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med. 2010;11:882-889. doi: 10.1016/j.sleep.2010.02.013.
16. Van Dongen HP, Baynard MD, Maislin G, et al. Systematic interindividual differences in neurobehavioral impairment from sleep loss: evidence of trait-like differential vulnerability. Sleep. 2004;27:423-433.
17. Moyle G, Fletcher C, Brown H, et al. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med. 2006;7:243-247.
18. Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2: 297-307.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-545.
20. Spielberger CD, Gorsuch RL, Lushene RE. Manual for State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press; 1970.
21. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
22. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4:97-110.
23. Grossman HA, Sullivan PS, Wu AW. Quality of life and HIV: current assessment tools and future directions for clinical practice. AIDS Read. 2003;13:583-590, 595-597.
24. Buysse DJ, Reynolds CF III, Monk TH, et al. The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213.
25. Gamaldo CE, Spira AP, Hock RS, et al. Sleep, function and HIV: a multimethod assessment. AIDS Behav. 2013 [epub ahead of print].
26. Wechsler D. Wechsler Adult Intelligence Scale - Revised Manual. New York, NY: The Psycholgical Corporation; 1981.
27. Reitan RM, Wolfson D. The Halstead - Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press; 1985.
28. Brandt J, Benedict R. HVLT-R. Lutz, FL: Psychological Assessment Resources, Inc; 2001.
29. Benedict R. Brief Visuospatial Memory Test-Revised. Odessa, FL: Psychological Assessment Resources, Inc; 2006.
30. Heaton RK, PAR staff. WCST-64:CV2. Research Edition. Lutz, FL: Psychological Assessments Resources, Inc; 2000.
31. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa; 1976.
32. Grooved Pegboard Test. Lafayette, IN: Lafayette Instruments; 1989.
33. Blair JR, Spreen O. Predicting premorbid IQ: a revision of the national adult reading test. Clin Neuropsychol. 1989;3:129-136.
34. Marder K, Albert SM, McDermott MP, et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology. 2003;60:1467-1473.
35. Concha M, Selnes OA, McArthur JC, et al. Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users. Int J Addict. 1995;30:823-841.
36. Selnes OA, Jacobson L, Machado AM, et al. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept Mot Skills. 1991;73:539-550.
37. Heaton R, Miler SW, Taylor MJ, et al. A Professional Manual of the Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessement Resources, Inc; 2004.
38. Stewart AL, Ware JE. Measuring Function and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1993.
39. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799.
40. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
41. Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci. 1993;242:329-336.
42. American Sleep Disorders Association. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. Vol 2. Westchester, IL: American Academy of Sleep Medicine; 2005.
43. Pearson VE, Allen RP, Dean T, et al. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med. 2006;7:25-30.
44. Darko DF, Miller JC, Gallen C, et al. Sleep electroencephalogram deltafrequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1995;92:12080-12084.
45. Kraft-Terry SD, Stothert AR, Buch S, et al. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37:542-548. doi: 10.1016/j.nbd.2009.12.015.
46. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084-2090.
47. Ragin AB, Wu Y, Ochs R, et al. Biomarkers of neurological status in HIV infection: a 3-year study. Proteomics Clin Appl. 2010;4:295-303. doi:10.1002/prca.200900083.
48. Clinton JM, Davis CJ, Zielinski MR, et al. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med. 2011;7(5 suppl):S38-S42. doi: 10.5664/JCSM.1360.
49. Born J, Lange T, Hansen K, et al. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol. 1997;158:4454-4464.
50. Mayhan WG. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res. 2002;927: 144-152.
51. Wang W, Lv S, Zhou Y, et al. Tumor necrosis factor-alpha affects bloodbrain barrier permeability in acetaminophen-induced acute liver failure. Eur J Gastroenterol Hepatol. 2011;23:552-558. doi: 10.1097/MEG.0b013e3283470212.
52. Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont). 2009;6:18-22.
53. Centers for Disease Control and Prevention (CDC). HIV prevalence estimates-United States, 2006. MMWR Morb Mortal Wkly Rep. 2008; 57:1073-1076.
54. Jena A, Sachdeva RK, Sharma A, et al. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic). 2009;8:318-322.
55. Kenedi CA, Goforth HW. A systematic review of the psychiatric sideeffects of efavirenz. AIDS Behav. 2011;15:1803-1818.
56. Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25:57-63.
57. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006; 7:544-548.
58. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10:343-355.
59. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24: 1243-1250. doi:10.1097/QAD.0b013e3283354a7b.
60. Ettenhofer ML, Hinkin CH, Castellon SA, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry. 2009;17:281-290.